SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Arcutis Enrolls First Patient in Phase 3 ZORYVE Atopic Dermatitis Trial

The Phase 3 INTEGUMENT-3 trial is evaluating once-daily ZORYVE cream 0.3% in patients age 6 and older with moderate to severe atopic dermatitis.

ARQT

Related stories